Scientists stunned by species' remarkable behavior after being moved from captivity to wild: 'This is pretty big news'
The axolotl — an often smiley-faced salamander known for its ability to regenerate limbs and organs — is showing new powers of adaptability, as individuals bred in captivity are surviving releases into the wild, according to a recent study.
The research has sparked optimism for protecting these unusual creatures that are critically endangered in their native habitat, NPR reported in early May.
Researchers tracked 18 axolotls that had been bred in captivity and released in artificial and restored natural wetlands in southern Mexico City in 2017 and 2018, per the news outlet. They found that animals in the study were hunting, eating, and avoiding predators. The axolotls weren't just surviving but thriving and gaining weight.
"This is pretty big news because when you have animals in captivity, they lose a lot of their behaviors," Alejandra Ramos, the study's lead researcher, told NPR. "Like, they don't know how to recognize a predator, they don't know how to catch prey, and so we were a bit nervous when we released them because we didn't know if they were going to be able to survive."
Axolotls — whose name is connected to Xolotl, the Aztec fire and lightning god — are sometimes called Mexican salamanders, water monsters, or water dogs. Native to lakes in the Mexico City area, they have caught the attention of animal lovers the world over for their distinctive colors and seemingly amiable expressions. They've even become popular pets.
Only about 50 to 1,000 axolotl adults live in the wild, though, according to the Natural History Museum in London. Their numbers have dropped significantly because of factors such as habitat loss and environmental change — sometimes connected to pollution and global temperature increases — as well as overfishing, collection by humans, and dangers from invasive species.
The discovery that captive-bred axolotls can be reintroduced to natural habitats offers hope that wild populations could be re-established. On top of this is the good news that the study's salamanders were able to survive in habitats created by and restored by humans — which bodes well for local preservation efforts.
"If axolotls could survive in man-made habitats, it could help scale back the damaging effects of habitat degradation and climate change," the NPR report summarized.
Saving axolotls could have specific benefits to people, as scientists are still working to understand the animals' cancer-resistant qualities and regenerative bodies. The hope is that studying their unique characteristics could lead to breakthroughs for human health.
Meanwhile, there is strong support for protecting axolotls for their own sake and as indicators of healthy, functioning habitats. There have even been programs to adopt axolotls to save them.
Should the government be paying people to hunt invasive species?
Definitely
Depends on the animal
No way
Just let people do it for free
Click your choice to see results and speak your mind.
In the NPR report, Ramos noted a special significance for the Mexican researchers. "They're part of our culture, they're part of our history. And that makes them really special to us," she said.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 hours ago
- Medscape
Nonsurgical Options Show Modest Benefit in Chronic Back Pain
In people with nonspecific chronic low back pain, nonsurgical interventions like cognitive-behavioral therapy and mindfulness possibly showed small-to-moderate long-term benefits in reducing pain intensity and disability. However, the evidence was mostly of low-to-moderate certainty. METHODOLOGY: Researchers conducted a systematic review and meta-analysis of 75 randomized or cluster randomized controlled trials involving 15,395 participants aged 16 years or older (mean age, 45.7 years; median percentage of women, 61%) with chronic low back pain lasting at least 12 weeks. They assessed the effectiveness of nonsurgical interventions for chronic low back pain (including 91% trials on nonspecific chronic low back pain) with a focus on long-term (1-2 years) and very long-term (≥ 2 years) outcomes. Psychological, physical, and combination nonsurgical interventions, including cognitive-behavioral therapy, mindfulness, and multidisciplinary care, were assessed, with exercise being the most frequently assessed intervention. Interventions were compared with placebo or sham, adjuvant interventions, no intervention, or usual care. Pain intensity and disability were assessed using scales like the Numerical Pain Rating Scale and Oswestry Disability Index, respectively, along with other measures, and the certainty of evidence was assessed. TAKEAWAY: At long-term follow-up, small-to-moderate reductions in pain intensity and disability were possibly seen with cognitive-behavioral therapy (mean differences, -7.2 and -5.7, respectively) and mindfulness (mean differences, -10.0 and -9.3, respectively) in individuals with nonspecific chronic low back pain. The evidence was of moderate certainty. Goal setting and needling interventions probably resulted in small reductions in disability, with mean differences of -8.3 and -4.8, respectively. Multicomponent biopsychosocial care and behavioral therapy might have led to moderate and small reductions, respectively, in pain intensity in those with nonspecific chronic low back pain (mean differences, -10.2 and -7.4, respectively; low-certainty evidence). Multidisciplinary care could have led to small reductions in disability (mean difference, -8.3). At very long-term follow-up, multidisciplinary care may have led to a moderate reduction in pain intensity (mean difference, -10.1), whereas exercise may have resulted in a moderate decrease in disability (mean difference, -10.2) in those with nonspecific chronic low back pain. The evidence was mostly of low certainty. IN PRACTICE: 'Although we identified some interventions with long-term effects for people with chronic low back pain, the clinical importance of the effects is uncertain,' the study authors wrote. 'Greater attention is needed on developing and testing interventions with long-term effects for chronic low back pain.' SOURCE: The study was led by Hazel J. Jenkins, PhD, Macquarie University, Sydney, Australia. It was published online on May 28, 2025, in The Lancet Rheumatology . LIMITATIONS: The certainty of the evidence was reduced for most comparisons because of the quality of the studies and inconsistencies in the results. DISCLOSURES: The study reported receiving no specific funding. Some authors reported receiving grants, support for attending meetings, research fellowships, and serving as members of the executive board of the network and/or as members of associations outside the submitted work.
Health Line
16 hours ago
- Health Line
Primary Progressive MS: Myths vs. Facts
Misconceptions about primary progressive multiple sclerosis (PPMS) are common, especially since the condition can look different for everyone. Knowing what's true (and what's not) can help you feel more informed and empowered. Primary progressive multiple sclerosis (PPMS) is a complex condition that looks different from person to person. Symptoms, experiences, and rates of progression can vary widely. Because PPMS isn't as well-known as other types of multiple sclerosis (MS), myths and misconceptions often fill the gaps. That can make it harder to find trustworthy answers when you're trying to learn more about the condition. Here, we break down some of the most common myths about PPMS and share the facts behind them. Myth#1: There will never be a cure for PPMS Fact: While there's no cure yet, treatment options are expanding, and research is ongoing. In 2017, the Food and Drug Administration (FDA) approved Ocrevus (ocrelizumab) as the first disease-modifying therapy (DMT) for PPMS. In 2024, a new formulation called ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), a subcutaneous injection administered twice a year, was approved. This new injection offers a quicker, approximately 10-minute administration alternative to the traditional intravenous infusion. Ocrevus and Ocrevus Zunovo are currently the only FDA-approved DMTs for PPMS. However, researchers are actively exploring new therapies. For instance, tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is undergoing phase 3 trials to assess its potential in slowing PPMS progression. Additionally, scientists are investigating treatments aimed at repairing myelin, the protective sheath around nerves damaged in MS. One such study involves combining metformin, a common diabetes medication, with clemastine, an antihistamine, to promote myelin repair. Myelin repair is important because it may help restore nerve function and slow disease progression. Although a cure for PPMS has yet to be found, these developments reflect a growing commitment to improving treatment options and outcomes. Myth: PPMS primarily occurs in females Fact: PPMS affects people of all sexes at the same rate. While relapsing-remitting multiple sclerosis (RRMS) is more common in people assigned female at birth (AFAB), affecting them two to three times more often than those assigned male at birth (AMAB), PPMS affects AFABs and AMABs in roughly equal numbers. It's important not to assume the type of MS based solely on sex. Regardless of gender, if you experience symptoms suggestive of MS, consult a healthcare professional for an accurate diagnosis. Myth: PPMS is an older person's disease Fact: PPMS typically begins in mid-adulthood, not old age. While PPMS tends to have a later onset than other forms of MS, it doesn't primarily affect older adults. On average, people with PPMS start experiencing symptoms around the age of 40. Myth: A PPMS diagnosis means you'll be disabled Fact: Disability progression in PPMS varies widely, and many people maintain mobility and independence for years. PPMS can lead to physical disability, but how quickly or whether it develops looks different for everyone. Some people notice gradual changes, while others may stay stable for long stretches of time. Not everyone will need mobility aids like canes or wheelchairs, especially early on. A 2022 study found that about 10% of people with MS experience severe disability within 5 years of diagnosis. That number rises to 25% within 10 years and then increases to 50% after 18 years. Still, this doesn't mean you should expect disability after receiving a PPMS diagnosis. The location of lesions, your overall health, and how early you begin treatment can all play a role in how the condition progresses. Working with your doctor on a treatment plan that includes physical or occupational therapy and regular movement can help you stay active and independent for longer. Myth: Having PPMS means you have to quit your job Fact: Many people with PPMS continue working, sometimes with a few adjustments. A PPMS diagnosis doesn't automatically mean you need to stop working. While symptoms like fatigue, changes in memory or thinking, or mobility issues can make certain jobs more challenging, many people with PPMS continue in full- or part-time work, especially in the early stages. Everyone's experience with PPMS is different, so your ability to work will depend on your specific symptoms and the demands of your job. If you're facing obstacles, workplace accommodations, like flexible hours, assistive devices, or ergonomic adjustments, may help you stay on the job. A conversation with your doctor or a vocational (work) counselor who understands chronic conditions can also help you explore options that support your health and independence. Myth: No medications help PPMS, so you should investigate natural remedies Fact: There are FDA-approved medications that can help slow the progression of PPMS, including ocrelizumab. While some natural remedies might offer symptom relief, they aren't always safe or proven to be effective. For years, there were no FDA-approved treatments for PPMS. That changed in 2017 when Ocrevus (ocrelizumab) became the first medication approved specifically for PPMS. In a study of 732 people with PPMS, those who received Ocrevus experienced a slower rate of disability progression compared to those who received a placebo. It remains the only approved disease-modifying therapy for this form of MS. Doctors may also prescribe medications to manage specific symptoms, such as antidepressants for mood changes or muscle relaxants for spasms. Some people turn to natural remedies like herbal supplements, acupuncture, or cannabis. Research into these options is ongoing, but so far, there's no strong evidence that they're safe or effective for treating MS symptoms. Some supplements can even interact with prescription drugs. If you're considering natural treatments, talk with your doctor first to avoid potential side effects or interactions. Myth: PPMS is ultimately an isolating disease — no one will understand what you're going through Fact: You're not alone, and you don't have to go through it alone either. While PPMS can feel isolating at times, many others are navigating similar challenges. It's estimated that nearly 1 million people in the United States are living with MS, and about 10% to 15% of them have PPMS. Thanks to growing awareness and advocacy, there are now more resources and support networks than ever. Support groups, both in-person and online, offer a space to connect with others who understand what you're going through. If group support isn't for you, that's OK too. Talking with a trusted friend, loved one, or therapist can still help ease feelings of isolation and improve emotional well-being. What matters most is finding a form of support that feels right for you. Myth: PPMS is deadly Fact: PPMS is a lifelong condition, but it's rarely fatal. The progressive nature of PPMS and the fact that there's no cure can understandably lead to fears about long-term outcomes. But while PPMS can affect mobility, thinking, and daily functioning, it's not considered a life threatening illness. Most people with MS who don't have severe disabilities can expect to live another 30 to 35 years after diagnosis. Recent research has shown that even after significant disease progression, many people continue to live for years. For example, after someone loses the ability to walk independently, on average, at around age 51, life expectancy is about 13 more years. Advances in treatment, early intervention, and lifestyle changes can help manage symptoms, reduce complications, and support overall health. Taking care of your physical and emotional well-being through exercise, a balanced diet, regular checkups, and support can make a big difference in quality of life. It's important to note that with ongoing advances in treatment, the outlook for people with PPMS continues to improve. Current data on disability and life expectancy may not reflect what's possible in the future. Takeaway Misconceptions about primary progressive multiple sclerosis (PPMS) can add confusion and fear to an already complex condition. However, the reality is that PPMS doesn't always follow the path people expect. From treatment options to life expectancy, the facts paint a more hopeful and nuanced picture. While every experience with PPMS is different, understanding the reality behind the myths can help you make informed choices, find support, and feel more in control of your journey.
Bloomberg
19 hours ago
- Bloomberg
Biotech Start-Ups Feel the Pain of Federal Funding Cuts
The Trump administration's attack on the National Institutes of Health is strangling the biotech industry's innovation engine — and it could get much worse. The ongoing, brutal termination of grant funding for academic research has rightfully dominated the headlines. These cuts will eventually become a real problem, as fewer dollars mean fewer discoveries to be pulled from academia and into biotech and pharmaceutical companies.
